Across the recent three months, 11 analysts have shared their insights on ACADIA Pharmaceuticals ACAD, expressing a variety ...

In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc.

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India's largest listed pharma company, ...

"attachment_1202489" align="aligncenter" width="1456"] A research scientist looking through a microscope in a lab, ...

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and ...

Harmony Biosciences continues to deliver strong sales and earnings growth, driven by its flagship drug WAKIX and a ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his price target from $400 to $500.

HDFC AMC and other leading asset managers heavily invested in Jubilant Bhartia Group's NCDs, which aimed to raise ₹5,650 ...